Apellis Pharmaceuticals Inc
NASDAQ:APLS

Watchlist Manager
Apellis Pharmaceuticals Inc Logo
Apellis Pharmaceuticals Inc
NASDAQ:APLS
Watchlist
Price: 24.965 USD 1.15% Market Closed
Market Cap: 3.2B USD
Section:
 

Relative Value

The Relative Value of one APLS stock under the Base Case scenario is 56.629 USD. Compared to the current market price of 24.965 USD, Apellis Pharmaceuticals Inc is Undervalued by 56%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

APLS Relative Value
Base Case
56.629 USD
Undervaluation 56%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

3.1
P/S
P/S
Price to Sales
3.1
vs History
90
vs Industry
67
Median 3Y
9.1
Median 5Y
17.4
Industry
7.9
Forward
3.1
More Details
70.2
P/E
P/E
Price to Earnings
70.2
vs History
0
vs Industry
Median 3Y
-12.7
Median 5Y
-10.9
Industry
24
Forward
94.1
More Details
40
P/OCF
P/OCF
Price to OCF
40
vs History
4
vs Industry
Median 3Y
-11.9
Median 5Y
-11.9
Industry
21.6
More Details
82.4
P/FCFE
P/FCFE
Price to FCFE
82.4
vs History
0
vs Industry
Median 3Y
-11.7
Median 5Y
-11.7
Industry
23.7
More Details
7.9
P/B
P/B
Price to Book Value
7.9
vs History
84
vs Industry
6
Median 3Y
17.9
Median 5Y
17.9
Industry
3.4
More Details
3
EV/S
EV/S
Enterprise Value to Sales
3
vs History
92
vs Industry
56
Median 3Y
9.1
Median 5Y
16.3
Industry
8.3
Forward
3
More Details
3.4
EV/GP
EV/GP
Enterprise Value to Gross Profit
3.4
vs History
80
vs Industry
58
Median 3Y
10.5
Median 5Y
12.6
Industry
10.3
More Details
37
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
37
vs History
0
vs Industry
Median 3Y
-13.9
Median 5Y
-13.1
Industry
6.7
Forward
35.3
More Details
37.8
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
37.8
vs History
0
vs Industry
Median 3Y
-13.8
Median 5Y
-13
Industry
7.2
Forward
45.1
More Details
38.5
EV/OCF
EV/OCF
Enterprise Value to OCF
38.5
vs History
4
vs Industry
Median 3Y
-11.8
Median 5Y
-11.6
Industry
8.2
More Details
38.7
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
38.7
vs History
4
vs Industry
Median 3Y
-11.8
Median 5Y
-11.6
Industry
6.7
More Details
5.6
EV/IC
EV/IC
Enterprise Value to IC
5.6
vs History
93
vs Industry
25
Median 3Y
9.6
Median 5Y
23.6
Industry
5.7
More Details

Multiples Across Competitors

APLS Competitors Multiples
Apellis Pharmaceuticals Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Apellis Pharmaceuticals Inc
NASDAQ:APLS
3.2B USD 3.1 70.2 37 37.8
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 794 036.5 -160 618 -195 041.5 -192 815.9
US
Abbvie Inc
NYSE:ABBV
395.9B USD 6.6 168.6 16.3 23.2
US
Amgen Inc
NASDAQ:AMGN
170.8B USD 4.7 24.4 17.7 17.7
US
Gilead Sciences Inc
NASDAQ:GILD
153B USD 5.3 18.9 12.7 12.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
113.3B USD 9.7 30.8 22.6 23.6
US
Epizyme Inc
F:EPE
94.1B EUR 2 084.7 -531.9 -579.2 -563.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.6B USD 5.5 17.2 16.3 18.5
AU
CSL Ltd
ASX:CSL
89.1B AUD 3.8 19.8 13.3 16.5
NL
argenx SE
XBRU:ARGX
46.5B EUR 15.1 35.4 61.6 63.3
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
54.4B USD 16.9 1 248.3 164.2 199.1
P/E Multiple
Earnings Growth PEG
US
Apellis Pharmaceuticals Inc
NASDAQ:APLS
Average P/E: 181.5
70.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 618 N/A N/A
US
Abbvie Inc
NYSE:ABBV
168.6
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
24.4
45%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
18.9
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
30.8
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -531.9 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.2
9%
1.9
AU
CSL Ltd
ASX:CSL
19.8
11%
1.8
NL
argenx SE
XBRU:ARGX
35.4
40%
0.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 248.3
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Apellis Pharmaceuticals Inc
NASDAQ:APLS
Average EV/EBITDA: 40.2
37
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 041.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.3
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
17.7
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.7
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.6
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -579.2 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.3
11%
1.5
AU
CSL Ltd
ASX:CSL
13.3
8%
1.7
NL
argenx SE
XBRU:ARGX
61.6
807%
0.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
164.2
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Apellis Pharmaceuticals Inc
NASDAQ:APLS
Average EV/EBIT: 45.8
37.8
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 815.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.2
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
17.7
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.7
12%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.6
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -563.8 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.5
13%
1.4
AU
CSL Ltd
ASX:CSL
16.5
11%
1.5
NL
argenx SE
XBRU:ARGX
63.3
N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
199.1
N/A N/A

See Also

Summary
APLS intrinsic value, competitors valuation, and company profile.
DCF Valuation
APLS stock valuation using Discount Cash Flow valuation method.
Relative Valuation
APLS stock valuation using valuation multiples.
Wall Street Estimates
APLS price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
APLS stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 302,500+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.